Radiation Therapy Oncology Group 0521: a phase III randomized trial of androgen suppression and radiation therapy versus androgen suppression and radiation therapy followed by chemotherapy with docetaxel/prednisone for localized, high-risk prostate cancer.
Patel
Asmita R
AR
Sinai Grace Hospital, Detroit Medical Center/Wayne State University, MI, USA.
Sandler
Howard M
HM
Pienta
Kenneth J
KJ
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000726:Androgen Antagonists / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D000077143:Docetaxel; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011241:Prednisone / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000473:pathology / Q000628:therapy*; D011878:Radiotherapy; D016019:Survival Analysis; D043823:Taxoids / Q000627:therapeutic use*; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D000726:Androgen Antagonists; D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D011241:Prednisone